qinlock Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Qinlock patents expire, and when can generic versions of Qinlock launch?
Qinlock is a drug marketed by Deciphera Pharms and is included in one NDA. There are seven patents protecting this drug.
This drug has forty patent family members in twelve countries.
The generic ingredient in QINLOCK is ripretinib. Additional details are available on the ripretinib profile page.
DrugPatentWatch® Generic Entry Outlook for Qinlock
Qinlock will be eligible for patent challenges on May 15, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 30, 2040. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for qinlock
International Patents: | 40 |
US Patents: | 7 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 1 |
What excipients (inactive ingredients) are in qinlock? | qinlock excipients list |
DailyMed Link: | qinlock at DailyMed |

DrugPatentWatch® Estimated Generic Entry Opportunity Date for qinlock
Generic Entry Date for qinlock*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for qinlock
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Deciphera Pharmaceuticals LLC | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for qinlock
US Patents and Regulatory Information for qinlock
qinlock is protected by seven US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of qinlock is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting qinlock
Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
Amorphous kinase inhibitor formulations and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
Methods of treating gastrointestinal stromal tumors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
FDA Regulatory Exclusivity protecting qinlock
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Deciphera Pharms | QINLOCK | ripretinib | TABLET;ORAL | 213973-001 | May 15, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for qinlock
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Deciphera Pharmaceuticals (Netherlands) B.V. | Qinlock | ripretinib | EMEA/H/C/005614 Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. |
Authorised | no | no | yes | 2021-11-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for qinlock
When does loss-of-exclusivity occur for qinlock?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Taiwan
Patent: 2136257
Estimated Expiration: See Plans and Pricing
Patent: 2136258
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering qinlock around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2010503701 | See Plans and Pricing | |
Australia | 2007296450 | Kinase inhibitors useful for the treatment of proliferative diseases | See Plans and Pricing |
South Korea | 20110074633 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |